ArticleDrug design, development and therapy2025
Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anlotinib and bevacizumab have demonstrated efficacy in treating HER-2 (human epidermal growth factor receptor 2)-negative metastatic breast cancer (MBC), yet no comparative studies have been conducted to access their effectiveness in MBC patients. Accordingly, this study aimed to evaluate the safety and effectiveness of anlotinib versus bevacizumab when combined with taxane/capecitabine for second-line or subsequent treatment of HER-2-negative MBC. Methods: Patients with pathologically confirmed HER-2-negative MBC that underwent second-line or subsequent treatment of anlotinib or bevacizumab plus taxane/capecitabine between April 2020 and October 2021 were retrospectively reviewed. Outcomes including the objective response rates (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were analyzed. Results: A total of 130 patients were included for this study, with 67 in the anlotinib + chemotherapy group and 63 in the bevacizumab + chemotherapy group. The ORRs were 40.30% for the anlotinib + chemotherapy group and 30.16% for the bevacizumab + chemotherapy group (P = 0.27), while the DCRs were 86.57% and 69.84%, respectively (P = 0.03). Patients in the anlotinib + chemotherapy group showed significantly longer median PFS and OS compared to the bevacizumab + chemotherapy group (mPFS: 8.57 vs 5.90 months, HR 0.55 [95% CI 0.36-0.85], P = 0.04; mOS: 22.76 vs 16.50 months, HR 0.63[95% CI 0.43-0.93], P = 0.02). The most common treatment-related adverse events (TRAE) were grade 1/2 alopecia, peripheral neuropathy, hypertension, and granulocytopenia, with both groups exhibiting tolerable TRAE profiles. Conclusion: In this retrospective analysis, anlotinib combined with taxane/capecitabine demonstrated a manageable safety profile. This regimen was associated with improved DCR, PFS, and OS compared to bevacizumab plus chemotherapy in patients with HER2-negative MBC. These findings suggest that anlotinib may represent a promising therapeutic option for patients for whom ADC drugs are inaccessible or unsuitable; however, further prospective, randomized studies are warranted to confirm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.